Coloplast A/S
Coloplast A/S (CLPBF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
clpbf · pe ratio · data through Sep 30, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Coloplast A/S (CLPBF) measures how much investors pay for each dollar of the company's trailing earnings. CLPBF's current PE ratio of 41.06x is calculated by dividing its stock price of $57.56 by its TTM earnings per share of $9.34. +10.5% elevated vs 5Y avg 37.1x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-09-30
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 20 fiscal years · Front-end computedMinQ1 · 25%33.2x
MedianQ3 · 75%111.5x
Max
At 41.06x, CLPBF's current P/E is higher than in 75% of its annual fiscal year readings over the past 20 years — historically elevated.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Medical - Devices · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Coloplast A/SYou CLPBF | $11.9B | 41.06x | -17.4% | $9.34 |
 Wellbeing Digital Sciences Inc. KONEF | $0M | N/A | — | -$0.21 |
 Orion Oyj ORINY | $22.9B | 36.71x | -26.2% | $0.85 |
 Straumann Holding AG SAUHF | $19.0B | 41.68x | -16.2% | $2.24 |
 Straumann Holding AG SAUHY | $18.9B | 43.20x | -13.1% | $0.21 |
 Sino Biopharmaceutical Limited SBHMY | $11.6B | 50.31x | +1.2% | $2.53 |
 Sartorius Stedim Biotech S.A. SDMHF | $20.0B | 76.73x | +54.3% | $2.73 |
Industry Average 5 peers with valid PE | — | 49.73x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-09-30Latest FY2025 | 33.36x | $16.10 | -13.8% | |
2024-09-30 FY2024 | 38.70x | $22.46 | +16.8% | |
2023-09-30 FY2023 | 33.12x | $22.20 | -2.3% | |
2022-09-30 FY2022 | 33.92x | $22.15 | -27.2% | |
2021-09-30 FY2021 | 46.62x | $22.67 | -9.4% | |
2020-09-30 FY2020 | 51.48x | $19.74 | +11.7% | |
2019-09-30 FY2019 | 46.08x | $18.24 | +26.2% | |
2018-09-30 FY2018 | 36.52x | $18.12 | +31.7% | |
2017-09-30 FY2017 | 27.74x | $17.89 | -19.4% | |
2016-09-30 FY2016 | 34.42x | $14.85 | -69.1% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Coloplast A/S (CLPBF) measures how much investors pay for each dollar of the company's trailing earnings. CLPBF's current PE ratio of 41.06x is calculated by dividing its stock price of $57.56 by its TTM earnings per share of $9.34.
Frequently asked questions
CLPBF pe ratio · 6 questionsCLPBF's current PE ratio is 41.06x as of 2026-06-08, based on a stock price of $57.56 and TTM EPS of $9.34. Data sourced from Financial Modeling Prep via CLPBF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Coloplast A/S SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08